Orli Megged1. 1. Pediatric Department and Infectious Diseases Unit, Shaare Zedek Medical Center affiliated with Hebrew University-Hadassah School of Medicine, P.O.B. 3235, Jerusalem, Israel, orlimegged@yahoo.com.
Abstract
BACKGROUND: Extended-spectrum β-lactamase (ESBL)-producing bacteria are infrequent pathogens of community-acquired (CA) urinary tract infections (UTIs) in children. The aim of this study was to assess the frequency of and identify risk factors for CA-UTIs due to ESBL-producing microorganisms (CA-ESBL-UTI). METHODS: The medical records of all children diagnosed with CA-ESBL-UTI at our medical center between 2003 and 2013 were reviewed. Patients with non-ESBL-UTIs during the same period were included as controls. RESULTS: Eighty cases of CA-ESBL-UTI were identified. The incidence of ESBL-UTI increased from 2 to 3.8% during the study period. Compared to children with non-ESBL-UTI, those with ESBL were more likely to be of Arab descent, to have underlying medical conditions, to have received antibiotics in the month prior to the UTI and to have been previously hospitalized. The mean duration of hospitalization for patients with an ESBL-UTI was significantly longer than that for patients with a non-ESBL UTI (3.6 vs. 2 days; P = 0.01). In multivariate analysis, Arab ethnicity [odds ratio (OR) 6.1; 95 % confidence interval (CI) 2.7-13.6] and recent antibiotic treatment (OR 4.0; 95 % CI 1.6-10.4) were risk factors for CA-ESBL-UTI. CONCLUSIONS: The incidence of CA-ESBL-UTI is rising. The empiric treatment for suspected UTI in children who had been previously hospitalized and who had received antibiotics in the last month should cover ESBL-producing bacteria.
BACKGROUND: Extended-spectrum β-lactamase (ESBL)-producing bacteria are infrequent pathogens of community-acquired (CA) urinary tract infections (UTIs) in children. The aim of this study was to assess the frequency of and identify risk factors for CA-UTIs due to ESBL-producing microorganisms (CA-ESBL-UTI). METHODS: The medical records of all children diagnosed with CA-ESBL-UTI at our medical center between 2003 and 2013 were reviewed. Patients with non-ESBL-UTIs during the same period were included as controls. RESULTS: Eighty cases of CA-ESBL-UTI were identified. The incidence of ESBL-UTI increased from 2 to 3.8% during the study period. Compared to children with non-ESBL-UTI, those with ESBL were more likely to be of Arab descent, to have underlying medical conditions, to have received antibiotics in the month prior to the UTI and to have been previously hospitalized. The mean duration of hospitalization for patients with an ESBL-UTI was significantly longer than that for patients with a non-ESBL UTI (3.6 vs. 2 days; P = 0.01). In multivariate analysis, Arab ethnicity [odds ratio (OR) 6.1; 95 % confidence interval (CI) 2.7-13.6] and recent antibiotic treatment (OR 4.0; 95 % CI 1.6-10.4) were risk factors for CA-ESBL-UTI. CONCLUSIONS: The incidence of CA-ESBL-UTI is rising. The empiric treatment for suspected UTI in children who had been previously hospitalized and who had received antibiotics in the last month should cover ESBL-producing bacteria.
Authors: Katherine E Goodman; Justin Lessler; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Jennifer H Han; Aaron M Milstone; Colin J Massey; Pranita D Tamma Journal: Clin Infect Dis Date: 2016-06-28 Impact factor: 9.079
Authors: Nuntra Suwantarat; Latania K Logan; Karen C Carroll; Robert A Bonomo; Patricia J Simner; Susan D Rudin; Aaron M Milstone; Tsigereda Tekle; Tracy Ross; Pranita D Tamma Journal: Infect Control Hosp Epidemiol Date: 2016-02-09 Impact factor: 3.254
Authors: Danielle M Zerr; Arianna Miles-Jay; Matthew P Kronman; Chuan Zhou; Amanda L Adler; Wren Haaland; Scott J Weissman; Alexis Elward; Jason G Newland; Theoklis Zaoutis; Xuan Qin Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191
Authors: Sibani Das; Amanda L Adler; Arianna Miles-Jay; Matthew P Kronman; Xuan Qin; Scott J Weissman; C A Burnham; Alexis Elward; Jason G Newland; Rangaraj Selvarangan; Kaede V Sullivan; Theoklis Zaoutis; Danielle M Zerr Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: A Tratselas; M Simitsopoulou; A Giannakopoulou; I Dori; S Saoulidis; K Kollios; P Papaioannidou; S Pournaras; E Roilides Journal: Antimicrob Agents Chemother Date: 2014-09-15 Impact factor: 5.191
Authors: Rima H Hanna-Wakim; Soha T Ghanem; Mona W El Helou; Sarah A Khafaja; Rouba A Shaker; Sara A Hassan; Randa K Saad; Carine P Hedari; Rima W Khinkarly; Farah M Hajar; Marwan Bakhash; Dima El Karah; Imad S Akel; Mariam A Rajab; Mireille Khoury; Ghassan S Dbaibo Journal: Front Cell Infect Microbiol Date: 2015-05-26 Impact factor: 5.293
Authors: Kristopher T Kang; Karen Ng; Jennifer Kendrick; Peter Tilley; Joseph Ting; Shahrad Rassekh; Srinivas Murthy; Ashley Roberts Journal: Paediatr Child Health Date: 2019-02-05 Impact factor: 2.253